All In Biotech

Drug Trial Radar · NCT06278038

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Feb 22, 2024

Primary completion

Nov 10, 2024

Study completion Nov 19, 2024

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use.

Conditions

  • Major Depression Disorder

Interventions

  • Toludesvenlafaxine hydrochloride sustained-release tabletsDrug

    80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks

  • Venlafaxine hydrochloride sustained-release tabletsDrug

    75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Snaith-Hamilton Pleasure Scale (SHAPS) Total ScoreTime frame: Baseline and the end of week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.